Entera Bio Ltd. (ENTX) AI Stock Analysis

Entera Bio Ltd. is a clinical-stage biopharmaceutical firm that specializes in advancing and commercializing orally delivered large molecule therapeutics to address significant medical needs. The company's lead pipeline programs are EB612 and EB613. EB612 is currently in Phase II clinical trials for hypoparathyroidism, while EB613 has completed Phase II trials for osteoporosis and is in Phase I trials for non-union fractures treatment. Additionally, Entera Bio has a strategic research collaboration and license agreement with Amgen Inc. to develop clinical candidates targeting inflammatory diseases and other critical conditions. Founded in 2009, the firm is headquartered in Jerusalem, Israel.

Entera Bio's revenue has fluctuated at early development levels, moving from $571,000 in FY2021 to $134,000 in FY2022 and $14,000 in FY2023. In FY2024, revenue reached $181,000 with a growth rate of 1192.9% and an operating margin of -5295.6%, before falling 76.8% in FY2025 to $42,000 with an operating margin of -27450.0%. Over the five-year period from FY2020 to FY2025, revenue posted a CAGR of -35.1%. Net income was -$12.2M in FY2021 and -$11.4M in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $0, with quarterly revenue growth falling 100.0% year-over-year.

As of June 30, 2026, Entera Bio held $11.3M in cash and short-term investments against total debt of $425,000, leaving net cash of $10.9M. The company reported total assets of $19.5M, shareholders' equity of $7.3M, and a current ratio of 8.98. Debt-to-equity stood at 0.06. In FY2025, operating cash flow was -$7.4M, free cash flow was -$7.5M, and capital expenditures totaled $107,000. Over five years, the company's share count increased 75.9%.

Entera Bio trades at a price-to-book ratio of 67.3x, with a market capitalization of $465.9M and an enterprise value of $478.2M. In comparison, the median of its US-listed Healthcare peers carries a price-to-sales ratio of 4.1x, a trailing P/E of 24.6x, and an EV-to-EBITDA ratio of 12.0x. Over the past year, Entera Bio shares gained 11.2%, trailing the 16.8% return of the S&P 500 (SPY). Over a five-year period, the stock declined 40.7%, compared to an 83.0% gain for the benchmark index.

Wall Street coverage reflects 5 Strong Buy ratings, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell recommendations. The mean price target is $9.75, representing a target vs last close of 263.8% compared to the October 16, 2026 share price of $2.68. For the fiscal year ending December 31, 2026, analysts estimate revenue of $0 and an EPS of -$0.40. For the following fiscal year, 5 analysts project revenue of $0 and an EPS of -$0.42. The company beat EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 13, 2026.

This page is an AI-written research summary of Entera Bio Ltd. (ENTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ENTX income statement, ENTX balance sheet, ENTX key metrics, ENTX analyst forecast, ENTX chart. See the ENTX stock overview for the latest quote and news.